Results: 201 patients were studied; median age 74 years, 47% female. Atrial fibrillation was the main indication for warfarin [63%]. 48 patients [24%] presented with bleeding, of which 22 were classified as major bleeds. All patients with major bleeding received reversal treatment; with 64% receiving recommended triple therapy. 33% in the non-bleeding group received reversal treatment. Conclusion: There was reasonably good compliance with the guidelines, especially for patients with major bleeding. Vitamin K doses were suboptimal in a significant proportion of cases.
INTRODUCTION
An elevated INR is a major determinant in the risk of bleeding in anticoagulated patients. 1 , 2 Previous research has established a high prevalence of a supra-therapeutic INR in the Emergency Department [ED] population taking warfarin. 3 In 2004, the Warfarin Reversal Consensus Group, on behalf of the Australasian Society of Thrombosis and Haemostasis, published consensus guidelines for warfarin reversal. 1 The aim of this study was to determine whether patients taking warfarin who have an abnormally high INR measured in the ED are being treated according to those guidelines.
METHODS
This observational study was conducted by explicit retrospective medical record review. 4 The primary outcome of interest was the proportion of patients treated according to the Australasian guidelines for management of over-anticoagulation. Data was analysed using descriptive statistics. A study period, starting a year after the guidelines were disseminated, was chosen to allow time for the guidelines to have been implemented while giving a sample size such that reasonable conclusions could be drawn. Our aim was 150 patients. The study was approved as a quality improvement activity under the NHMRC Quality Assurance guidelines and formal ethics approval was not required.
RESULTS
201 patients were included in the analysis. The derivation of the sample is shown in Figure 1 . Figure 2 . 
DISCUSSION
This is the first Australian study to investigate compliance with the Warfarin Reversal Consensus Guidelines 1 in ED patients. We found reasonably good compliance with the guidelines for patients with major bleeding with respect to agents administered, but doses were below those recommended in a significant proportion of cases, especially for vitamin K. Treatment of non-bleeding patients with INR <5 (65 patients) was well adhered to. Most patients in that group did not receive any active treatment (95%), with warfarin doses omitted or reduced as is recommended by the guidelines. Treatment for the non-bleeding group escalated in line with INR, which is also consistent with the guidelines. This study did not allow us to evaluate the risk of bleeding perceived by the treating physician, which is a factor contributing to decision making in the guidelines. Variation in perceived risk may explain the small number of patients in the non-bleeding group who received treatments in addition to Vitamin K.
Similar studies have been conducted in the USA investigating compliance with the American College of Chest Physicians guidelines for reversal of warfarin 5 . In a scenario-based survey, Wilson et al 6 found poor compliance with the guidelines, with inappropriate dosages and routes of administration being common. Fan et al, in a retrospective study focusing on vitamin K administration to reverse the effects of warfarin, also found poor compliance with the guidelines. 7 Salamat in the UK reported that the introduction of guidelines did not improve use of prothrombin complex extract or vitamin K. 8 As we did not have pre-guideline data, we are unable to comment on whether the guideline improved practice in the study ED.
The administration of Vitamin K doses varied quite considerably in our study, with doses ranging from 0.5mg to 10mg. Errors were both over-treatment of non-bleeding patients and under-treatment of patients with major bleeding. The problem may be one of understanding the role of Vitamin K in each scenario; complete reversal in those with major bleeding and partial reversal in those without bleeding. Additionally, Prothrombinex was also prescribed less frequently than recommended for reasons that are not apparent.
The uptake of guidelines in clinical settings has been reported to have widely varying success: from very poor to good. Key success factors appear to be the quality and format of the guidelines, clinical leadership, the perceived relevance of the guidelines and dissemination/ implementation strategies. 9 That compliance with the warfarin reversal guidelines is reasonably good in this study [albeit in a single health service] suggest that the guidelines may be achieving reasonable uptake.
This study has some limitations that should be considered when interpreting the results. Data was collected by medical record review methodology, which is subject to well-known problems with documentation/ missing data. To minimise the problems associated with this method we used explicit data collection and clear, pre-defined definitions of terms. 
CONCLUSION
There was reasonably good compliance with the guidelines, especially for patients with major bleeding, with respect to agents administered, however doses were not optimal in a significant proportion of cases, particularly for Vitamin K.
